Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 4/20 | 0.33 |
| ▸ | TUBB | P07437 | 4/20 | 0.33 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.33 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.33 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.33 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.33 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.33 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.33 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.33 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.33 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.33 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.33 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.33 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.33 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2108725 | 1.00 | TUBB4A (0.33) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL2107149 | 0.87 | TUBB4A (0.32) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL2107147 | 0.87 | TUBB4A (0.32) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL2109403 | 0.82 | — | — | |
| SCHEMBL2109402 | 0.82 | — | — | |
| SCHEMBL2619834 | 0.82 | — | — | |
| SCHEMBL10280516 | 0.75 | TUBB4A (0.35) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL22881113 | 0.75 | — | — | |
| SCHEMBL2108688 | 0.74 | — | — | |
| SCHEMBL2619894 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2233474-B1 | CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2015-08-05 | — | — | EP | disclosed |
| US-8946210-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8946211-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-20130203741-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| US-20130203741-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| US-20120094984-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-8158620-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-8158620-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20100317850-A1 | CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-16 | — | — | US | disclosed |
| EP-2233474-A1 | CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-09-29 | — | — | EP | disclosed |
| US-20090209755-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090209755-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203741-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | TUBB4A 2482/4885TUBB 2014/4885TUBA3C 2006/4885 |
| US-20090209755-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | TUBB4A 2482/4885TUBB 2014/4885TUBA3C 2006/4885 |
| US-20120094984-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | TUBB4A 2482/4885TUBB 2014/4885TUBA3C 2006/4885 |
| US-20100317850-A1 | CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE | BACE1, APP, BACE2 | TUBB4A 2061/4885TUBB 1440/4885TUBA3C 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.